# Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells

> **NCT00398411** · PHASE3 · COMPLETED · sponsor: **University of Cologne** · enrollment: 66 (actual)

## Conditions studied

- Hodgkin Disease
- Non-Hodgkin Lymphoma
- Multiple Myeloma
- Bacteremia

## Interventions

- **DRUG:** moxifloxacin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00398411
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2015-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398411, "Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00398411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*